Tornai T, Palyu E, Vitalis Z, Tornai I, Tornai D, Antal-Szalmas P, Norman GL, Shums Z, Veres G, Dezsofi A, Par G, Par A, Orosz P, Szalay F, Lakatos PL, Papp M. Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis. World J Gastroenterol 2017; 23(29): 5412-5421 [PMID: 28839442 DOI: 10.3748/wjg.v23.i29.5412]
Corresponding Author of This Article
Maria Papp, MD, PhD, Institute of Internal Medicine, Department of Gastroenterology, University of Debrecen, Faculty of Medicine, Nagyerdei krt. 98, H-4032 Debrecen, Hungary. papp.maria@med.unideb.hu
Research Domain of This Article
Gastroenterology & Hepatology
Article-Type of This Article
Observational Study
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Table 3 Associations between gut failure markers and disease or laboratory characteristics in patients with primary sclerosing cholangitis at enrolment
Anti-F-actin IgA
Anti-F-actin IgG
Anti-gliadin IgA
Anti-gliadin IgG
Negative (n = 48)
Positive (n = 19)
P value
Negative (n = 50)
Positive (n = 17)
P value
Negative (n = 61)
Positive (n = 6)
P value
Negative (n = 53)
Positive (n = 14)
P value
Male gender, n (%)
35 (72.9)
13 (68.4)
0.713
38 (76.0)
10 (58.8)
0.175
44 (72.1)
4 (66.7)
0.777
37 (69.8)
11 (78.6)
0.518
Presence of cirrhosis, n (%)
8 (16.7)
5 (26.3)
0.368
9 (18.0)
4 (23.5)
0.618
11 (18)
2 (33.3)
0.366
10 (18.9)
3 (21.4)
0.829
Presence of IBD, n (%)
36 (75)
15 (78.9)
0.733
40 (80.0)
11 (64.7)
0.201
47 (77)
4 (66.7)
0.569
40 (75.5)
11 (78.6)
0.809
Median, IQR
Age at diagnosis (yr)
23 (17-33)
26 (18-37)
0.713
25 (17-37)
20 (11-31)
0.220
23 (17-35)
23 (18-29)
0.925
23 (17-37)
22 (17-29)
0.502
Disease duration (yr)
6 (3-8)
7 (2-12)
0.240
6 (4-10)
6 (1-9)
0.219
6 (3-9)
9 (1-12)
0.760
6 (3-8)
6 (2-17)
0.506
Albumin (g/L)
44 (42-46)
39 (38-47)
0.020
44 (40-46)
43 (39-47)
0.442
44 (40-47)
39 (39-42)
0.210
44 (40-46)
43 (39-47)
0.726
Bilirubin (μmol/L)
15 (11-20)
14 (11-37)
0.704
15 (11-20)
13 (10-22)
0.705
14 (10-22)
17 (16-21)
0.216
15 (11-23)
17 (12-20)
0.813
AST (U/L)
35 (25-56)
55 (37-94)
0.006
36 (27-56)
44 (34-85)
0.182
39 (28-61)
41 (34-48)
0.861
42 (28-61)
35 (25-55)
0.524
ALT (U/L)
46 (21-92)
65 (45-165)
0.030
50 (25-97)
55 (32-165)
0.532
52 (25-100)
44 (37-52)
0.294
54 (32-111)
42 (24-65)
0.188
GGT (U/L)
142 (45-269)
193 (112-478)
0.041
153 (63-305)
153 (60-420)
0.748
154 (60-310)
140 (93-305)
0.943
160 (54-310)
126 (88-305)
0.895
ALP (U/L)
406 (253-643)
1198 (595-1766)
< 0.001
469 (268-734)
715 (507-1496)
0.040
524 (312-784)
1204 (307-1299)
0.336
507 (326-746)
652 (268-1204)
0.394
PLT (G/L)
238 (181-292)
315 (162-494)
0.212
235 (175-274)
320 (162-466)
0.066
248 (165-316)
274 (232-494)
0.292
253 (165-316)
241 (187-356)
0.751
Mayo risk score
-0.834 (-1.378 to -0.131)
0.021 (-0.554-1.248)
0.016
-0.62 (-1.142-0.102)
-0.226 (-1.578-0.292)
0.623
-0.595 (-1.194-0.102)
0.021 (-0.843-1.327)
0.429
-0.579 (-1.102-0.174)
-0.651 (-1.194-0.021)
0.762
Table 4 Serum level of bacterial translocation and enterocyte damage markers according to the different serologic antibody statuses
Anti-F-actin IgA
Anti-F-actin IgG
Anti-gliadin IgA
Anti-gliadin IgG
Negative (n = 48)
Positive (n = 19)
P value
Negative (n = 50)
Positive (n = 17)
P value
Negative (n = 61)
Positive (n = 6)
P value
Negative (n = 53)
Positive (n = 14)
P value
Median, IQR
LBP (μg/L)
7132 (5150-9806)
7374 (4348-12100)
0.931
7377 (5795-9880)
6847 (3828-13300)
0.852
6959 (5044-9806)
11450 (5836-15200)
0.239
6959 (4951-9806)
8090 (6077-12700)
0.274
EndoCab IgA (U)
58 (40-92)
123 (93-215)
< 0.001
68 (49-97)
113 (52-150)
0.195
70 (43-106)
134 (66-241)
0.079
70 (43-112)
94 (52-150)
0.301
OMP Plus IgA, n (%)
5 (10.60)
7 (36.80)
0.012
11 (22)
1 (6.30)
0.155
12 (20)
0 (0)
0.226
11 (21.20)
1 (7.10)
0.228
I-FABP (pg/mL)
166 (90-365)
365 (203-1079)
0.011
199 (143-513)
300 (90-365)
0.794
216 (99-443)
342 (143-942)
0.642
195 (99-379)
342 (179-1020)
0.092
Citation: Tornai T, Palyu E, Vitalis Z, Tornai I, Tornai D, Antal-Szalmas P, Norman GL, Shums Z, Veres G, Dezsofi A, Par G, Par A, Orosz P, Szalay F, Lakatos PL, Papp M. Gut barrier failure biomarkers are associated with poor disease outcome in patients with primary sclerosing cholangitis. World J Gastroenterol 2017; 23(29): 5412-5421